The PRECISOCARE® Senior Program addresses the unique genomic clinical needs of patients 65 and older — where polypharmacy, late-onset hereditary conditions, cognitive aging, and multi-system complexity require a more sophisticated diagnostic and care coordination approach.
Senior patients present with compounding genomic considerations that span medication safety, late-onset hereditary conditions, aging-related disease risk, and complex care coordination needs.
Senior patients often take 5–10+ medications simultaneously. PRECISOCARE® PGx profiling identifies drug-gene interactions across the full medication burden — providing prescribing guidance that accounts for combined effects, not just individual drug metabolism.
Adverse drug reactions are among the leading causes of preventable hospitalization in adults 65+. PGx-guided prescribing has been shown to reduce adverse events and improve medication adherence in complex care populations.
Genomic profiling for APOE ε4 (Alzheimer's risk), LRRK2/GBA Parkinson variants, and other late-onset neurological conditions. Results inform monitoring frequency, preventive intervention timing, and advance care planning conversations.
Cognitive risk variants require pre-test and post-test genetic counseling to ensure patients and families can properly contextualize and act on results. PRECISOCARE® genetic counseling is available for all senior program participants.
Hereditary cardiomyopathy variants (including TTR amyloidosis — increasingly recognized as an underdiagnosed cause of heart failure in seniors), familial hypercholesterolemia, and arrhythmia predisposition. Informs cardiac surveillance intensity and treatment approach.
Many BRCA, Lynch syndrome, and other hereditary cancer variants first present with clinical cancer diagnoses in the 6th–8th decade. Genomic evaluation of senior cancer patients — and their first-degree relatives — can identify hereditary etiology and guide family cascade testing.
Hereditary osteoporosis risk variants, immune aging genomic markers, and connective tissue variants with late-onset manifestations. Results inform monitoring protocols and guide preventive interventions in high-risk senior populations.
For seniors in skilled nursing, memory care, or high-acuity settings — PRECISOCARE® provides structured genomic infrastructure that integrates into care team workflows and supports multi-disciplinary clinical decision-making at scale.
Senior patients typically have multiple providers — primary care, specialists, pharmacists, and care coordinators — who each benefit from genomic context. PRECISOCARE® delivers reports in a format designed for multi-provider clinical environments, not just single-episode care.
PHIN®-enabled connectivity ensures genomic findings and PGx results are accessible across the care continuum — so the patient's cardiologist, geriatrician, and pharmacist can all operate with the same genomic context without redundant testing.
Whether you serve seniors through primary care, geriatrics, cardiology, or institutional care settings — PRECISOCARE® can be structured to meet your program needs.